PsyPost
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Neuroscience
  • About
No Result
View All Result
Join
My Account
PsyPost
No Result
View All Result
Home Exclusive Mental Health Addiction

Psilocybin use was associated with lowered odds of opioid use disorder

by Emily Manis
April 22, 2022
Reading Time: 2 mins read
Share on TwitterShare on Facebook

Opioid abuse is a prevalent and very dangerous substance use disorder. Psychedelic use has been proposed as a treatment for various substance use disorders, leading people to question if it would be an effective treatment for opioid abuse. A study published in Nature: Scientific Reports suggests that psilocybin use, but no other psychedelics, was linked to lower odds of opioid abuse.

Opioid abuse is a serious and deadly public health crisis. It has a very high rate of death, accounting for around 70% of overdose deaths in the US. Since the start of the COVID-19 pandemic, this problem has only gotten increasingly worse. Despite the prevalence of opioid addiction, there are not many effective pharmacological treatments for it. Classic psychedelics have been used to treat different kinds of substance use disorder, though the research on this is still emerging and is somewhat limited.

Grant Jones and colleagues used data from The National Survey on Drug Use and Health from 2015 to 2019. This survey utilizes a nationally representative sample of the US, not including military members, incarcerated individuals, or people experiencing homelessness. Lifetime use of 4 commonly used psychedelics were the main independent variables used for this study. This study also utilized demographic information, self-reported risk behaviors, and lifetime use of other substances. The main dependent variable was meeting criteria for opioid use disorder.

Results showed that the only substance that was associated with lower chances of opioid use disorder was psilocybin. Psilocybin was related to lowered odds for 7 of the 11 DMS-IV criteria that make up opioid use disorder. Peyote, mescaline, and LSD did not have this same relationship, showing either no significant relationship or even an increase in opioid dependence. Psilocybin users who have or have not used opioids differed on all demographic traits measured by this study, which include sex, education, race, income, age, and marital status.

This study took steps into seeing if psychedelics may be a viable treatment for opioid abuse. Despite this, it has limitations. Though this study utilized a very large and representative sample, The National Survey on Drug Use and Health excludes some groups of people that may have high rates of drug abuse, including people experiencing homelessness. In addition, due to the cross-sectional nature of this study, no causal relationships can be assumed.

The study, “Associations between classic psychedelics and opioid use disorder in a nationally-representative US adult sample“, was authored by Grant Jones, Jocelyn A. Ricard, Joshua Lipson, and Matthew K. Nock.

Google News Preferences Add PsyPost to your preferred sources
TweetSendScanShareSendPinShareShareShareShareShare

Follow PsyPost

The latest research, however you prefer to read it.

Daily newsletter

One email a day. The newest research, nothing else.

Google News

Get PsyPost stories in your Google News feed.

Add PsyPost to Google News
RSS feed

Use your favorite reader.

Copy RSS URL
Social media
Support independent science journalism

Ad-free reading, full archives, and weekly deep dives for members.

Become a member

Trending

  • A specific thinking style explains why dark personality traits are linked to creativity
  • Adolescent narcissism brings brief popularity but not likeability among peers, study finds
  • A 20-minute workout protects memory after sleep loss just as well as a 90-minute nap
  • How personality and social context shape adolescent loneliness
  • Weightlifting offers large antidepressant effects for young women with anxiety, regardless of intensity

Science of Money

  • Why highly adaptable business clients aren’t always the most satisfied
  • The four ways underdog startups survive corporate giants
  • How AI-generated plain English changes investor interest in mutual funds
  • What 18 years of brokerage data reveals about selling losing stocks
  • When edgy brands meet manipulative consumers: The backfire effect of dark personalities

Recent

  • Researchers launch global tracking project to measure the daily mental health impacts of cannabis
  • New study challenges the core assumption behind the world’s most widely used implicit bias test
  • Common antidepressants might help liver cells clear a dangerous type of cholesterol
  • Massive study of over a million people identifies hundreds of genetic variants linked to personality
  • A child’s genetic profile for ADHD can predict their parents’ risk of separation
  • Universal two-child policy linked to increased depression among Chinese women
  • Are gender differences really power differences? Large-scale analysis finds strong behavioral parallels
  • Body roundness index linked to depression risk in older adults with dementia
  • A specific thinking style explains why dark personality traits are linked to creativity
  • Private touch matters more than public affection for relationship quality

PsyPost is a psychology and neuroscience news website dedicated to reporting the latest research on human behavior, cognition, and society. (READ MORE...)

  • Mental Health
  • Neuroimaging
  • Personality Psychology
  • Social Psychology
  • Artificial Intelligence
  • Cognitive Science
  • Psychopharmacology
  • Contact us
  • Disclaimer
  • Privacy policy
  • Terms and conditions

(c) PsyPost Media Inc

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy

(c) PsyPost Media Inc